Genomic & Biopharma News

Concordia reports $1.3B loss after taking $1.1B write-off on pressured generics
Concordia reports $1.3B loss after taking $1.1B write-off on pressured generics epalmer Wed, 03/15/2017 - 11:14
Fierce Pharma, 2017-03-15 15:14:35

The Science of Science Advocacy
Should researchers advocate for the inclusion of science in public policymaking?
The Scientist, 2017-03-15 15:00:00

Medtronic updates troubled SynchroMed infusion pump in class 1 recall
Medtronic updates troubled SynchroMed infusion pump in class 1 recall aalidrus Wed, 03/15/2017 - 10:50
Fierce Biotech, 2017-03-15 14:50:39

MetrioPharm advances psoriasis drug after phase 2 readout
MetrioPharm advances psoriasis drug after phase 2 readout nick.paul.taylor Wed, 03/15/2017 - 10:02
Fierce Biotech, 2017-03-15 14:02:10

Antibody Therapy Targets Cancer Stem Cells: Study
CT16 appears to eliminate cancer stem cells more effectively than radiation therapy in vitro and has shown promise in mice.
The Scientist, 2017-03-15 14:00:00

Researchers find increase in prescription of epipens for children with allergies
Researchers at the University of Birmingham have found that prescriptions of adrenaline autoinjectors (commonly called 'epipens') for children with allergies have increased markedly in the last decade, with nearly four devices a year provided per child.
News Medical Life Sciences, 2017-03-15 13:58:03

Neon taps lymph delivery specialist Vedantra for cancer vaccine project
Neon taps lymph delivery specialist Vedantra for cancer vaccine project phil Wed, 03/15/2017 - 09:57
Fierce Biotech, 2017-03-15 13:57:14

BioCapt Single-Use Microbial Impactor helps minimize false positives, eliminate costly sterilization steps
The BioCapt Single-Use Microbial Impactor, designed by and offered exclusively through Particle Measuring Systems, helps minimize false positives for microbial activity in pharmaceutical cleanrooms by reducing contamination from handling of microbial plates.
News Medical Life Sciences, 2017-03-15 13:55:44

After expert panel vote, Endo's opioid Opana ER faces FDA restrictions—or withdrawal
After expert panel vote, Endo's opioid Opana ER faces FDA restrictions—or withdrawal esagonowsky Wed, 03/15/2017 - 09:46
Fierce Pharma, 2017-03-15 13:46:59